CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 233 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $563,855 | -12.2% | 48,234 | +1.0% | 0.00% | -100.0% |
| Q2 2023 | $642,123 | -30.4% | 47,777 | -14.2% | 0.00% | 0.0% |
| Q1 2023 | $923,241 | +17.3% | 55,684 | +31.6% | 0.00% | 0.0% |
| Q4 2022 | $787,022 | +109.9% | 42,313 | +44.9% | 0.00% | – |
| Q3 2022 | $375,000 | +140.4% | 29,200 | +30.8% | 0.00% | – |
| Q2 2022 | $156,000 | +300.0% | 22,324 | +90.4% | 0.00% | – |
| Q4 2020 | $39,000 | +11.4% | 11,726 | 0.0% | 0.00% | – |
| Q3 2020 | $35,000 | -57.3% | 11,726 | -33.8% | 0.00% | – |
| Q2 2020 | $82,000 | +13.9% | 17,726 | -5.3% | 0.00% | – |
| Q1 2020 | $72,000 | -29.4% | 18,726 | -31.0% | 0.00% | – |
| Q4 2019 | $102,000 | -16.4% | 27,133 | +17.9% | 0.00% | – |
| Q3 2019 | $122,000 | +82.1% | 23,007 | +31.4% | 0.00% | – |
| Q2 2019 | $67,000 | +1.5% | 17,507 | +34.6% | 0.00% | – |
| Q1 2019 | $66,000 | +127.6% | 13,007 | -13.3% | 0.00% | – |
| Q4 2018 | $29,000 | -38.3% | 15,007 | +20.0% | 0.00% | – |
| Q3 2018 | $47,000 | – | 12,507 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 5,517,885 | $22,789,000 | 2.29% |
| March Altus Capital Management LP | 80,890 | $334,000 | 1.94% |
| TANAKA CAPITAL MANAGEMENT INC | 111,693 | $462,000 | 1.15% |
| PURA VIDA INVESTMENTS, LLC | 395,000 | $1,951,000 | 1.00% |
| Broadfin Capital, LLC | 4,183,177 | $17,277,000 | 0.93% |
| Catalyst Capital Advisors LLC | 1,310,000 | $5,411,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,200,000 | $4,956,000 | 0.48% |
| Baker Brothers Advisors | 7,335,692 | $30,296,000 | 0.27% |
| TURNER INVESTMENTS LLC | 286,370 | $1,183,000 | 0.22% |
| Perceptive Advisors | 851,200 | $3,515,000 | 0.21% |